1. Elevated serum FGF21 is an independent predictor for adverse events in hemodialysis patients from two large centers: a prospective cohort study
- Author
-
Min Li, Li-qiong Jiang, Meng-yu Zhang, Shu-su Liu, Rejean-Ruiel Regis Sawh, Jing Zheng, Yu Yan, Shi-mei Hou, Ke-qi Lu, Obadele Thorne, Bi-cheng Liu, Qing Qian, Yan-feng Wu, Min Yang, and Bin Wang
- Subjects
All-cause mortality ,fibroblast growth factor 21 ,hemodialysis ,major adverse cardiovascular events ,pneumonia ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Introduction We explored the relationship and the predictive value of serum fibroblast growth factor 21 (FGF21) with all-cause mortality, major adverse cardiovascular events (MACEs) and pneumonia in hemodialysis (HD) patients.Methods A total of 388 Chinese HD patients from two HD centers were finally enrolled in this prospective cohort study (registration number: ChiCTR 1900028249) between January 2018 and December 2018. Serum FGF21 was detected. Patients were followed up with a median period of 47 months to record the MACEs and pneumonia until death or 31 December 2022.Results The incidence of all-cause mortality, MACEs and pneumonia in HD patients were 20.6%, 29.6%, and 34.8%, respectively. The optimal cutoffs for FGF21 to predict all-cause mortality, MACEs and pneumonia were 437.57 pg/mL, 216.99 pg/mL and 112.79 pg/mL. Multivariate Cox regression analyses showed that FGF21, as a categorical variable, was an independent predictor for all-cause mortality, MACEs and pneumonia (HR, 3.357, 95% CI, 2.128–5.295, p
- Published
- 2023
- Full Text
- View/download PDF